PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review
DOI:
https://doi.org/10.11606/issn.1679-9836.v100i4p391-402Keywords:
Prostatic neoplasms, 177Lu-PSMA, Castration-resistant prostate cancer, Efficacy, Neoplasm metastasis, Radioligand therapy, Safety, Nuclear medicineAbstract
Prostate cancer is the second most prevalent in the world and an important cause of mortality in elderly men. Its most severe form is metastatic castration-resistant prostate cancer, difficult to control as it does not respond well to chemotherapy or androgen deprivation. A new treatment, based on PSMA ligands chelated to a Lutetium-177 atom, is a potential therapy for these patients, with evidence that it causes tumor regression. The goal of this systematic review is to evaluate the literature regarding the safety and efficacy of this new therapy
Downloads
References
Torre LA, Siegel RL, Ward EM, Jemal A. global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev. 2015;25(1):16-27. doi: 10.1158/1055-9965.EPI-15-0578.
Tourinho-Barbosa RR, Pompeo ACL, Glina S. Prostate cancer in Brazil and Latin America: epidemiology and screening. Int Braz J Urol. 2016;42(6):1081-90. doi: 10.1590/S1677-5538.
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. 177Lutetium-PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52-60. doi: 10.1002/jmrs.227.
Pezaro CJ, Marciscano AE, Madan RA. The winds of change: emerging therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book. 2018;(38):382-90. doi: 10.1200/EDBK_201295.
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807-11. Available from: https://cancerres.aacrjournals.org/content/canres/54/7/1807.full.pdf.
Rahbar K, Ahmadzadehfar H, Kratochwil C. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. doi: 10.2967/jnumed.116.183194.
Filss C, Heinzel A, Miiller B, Vogg A, Langen K-J, Mottaghy F. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Nuklearmedizin. 2018;57(01):19–25. doi: 10.3413/Nukmed-0937-17-10
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(2):243–6. DOI: 10.1007/s00259-017-3877-z.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017;45(1):12–9. doi: 10.1007/s00259-017-3848-4.
Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(10):1663–70. doi: http://dx.doi.org/10.1007/s00259-017-3751-z.
Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–3590. doi: 10.18632/oncotarget.12240.
Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177 Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med. 2016;58(3):445–50. doi: 10.2967/jnumed.116.178483.
Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177 Lu-PSMA-617. J Nucl Med. 2016;58(2):312–9. doi: 10.2967/jnumed.116.178228.
Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar I, et al. Evaluation of radiation safety in177Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016;36(2):269–78. doi: 10.1088/0952-4746/36/2/269.
Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand Therapy With 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med. 2016Jul;41(7):522–8. doi: 10.1097/RLU.0000000000001240.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57(9):1334–8. doi: 10.2967/jnumed.116.173757.
Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [177Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18(3):437–45. doi: 10.1007/s11307-016-0942-0.
Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477–12488. doi: 10.18632/oncotarget.7245
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–13. doi: 10.2967/jnumed.115.168443.
Kabasakal L, Abuqbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976–83. doi: 10.1007/s00259-015-3125-3.
Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810–6. doi: 10.1200/JCO.2009.25.7311.
Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522–8. doi: 10.1097/RLU.0000000000001240.
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [177Lu]-PSMA-617 in patients with metastatic prostate cancer. Eur J Nuclear Med Mol Imaging. 2018;46(5):1073–80. doi: 10.1007/s00259-018-4222-x
Yilmaz B, Nisli S, Ergul N, Gursu RU, Acikgoz O, Çermik TF. Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands. J Nuclear Med. 2019;60(10):1388–93. doi: 10.2967/jnumed.119.226449
Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester H-J, et al. Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. J Nuclear Med. 2018;60(5):644–8. doi: 10.2967/jnumed.118.215715
Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75(6):920–6. doi: 10.1016/j.eururo.2018.11.016
van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, et al. First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. Clin Nuclear Med. 2019;44(6):446–51. doi: 10.1097/RLU.0000000000002561
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. J Nuclear Med. 2019;60(7):955–62. doi: 10.2967/jnumed.118.216820
Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nuclear Med. 2020;45(1):19–31. doi: 10.1097/RLU.0000000000002833.
Özkan A, Uçar B, Seymen H, Yildiz Yarar Y, Falay FO, Demirkol MO. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer. Clin Nuclear Med. 2020;45(4):288–91. DOI: 10.1097/RLU.0000000000002942.
Hofman MS, Emmett L, Sandhu SK, Iravani A, Joshua AM, Goh JC, et al. TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). J Clin Oncol. 2020;38(15_suppl):5500–. doi: 10.1200/JCO.2020.38.15_suppl.5500.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang S-P, Kong G, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nuclear Med. 2019;61(6):857–65. doi: 10.2967/jnumed.119.236414.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Lucca Paolo Hsu Helmich, Marcelo Augusto Magalhães de Arruda, Marcelo Tatit Sapienza
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
